CENTEK(SZ:000931) Zheng Quan Shi Bao Wang·2025-10-14 07:51Core Viewpoint - The company Zhongguancun (000931) has received acceptance for the marketing authorization application of its drug, Sitagliptin Metformin Tablets, from the National Medical Products Administration, indicating a significant step in expanding its product portfolio in the diabetes treatment market [1] Company Summary - Zhongguancun's subsidiary, Duoduo Pharmaceutical Co., Ltd., has recently received the acceptance notice for the marketing authorization application of Sitagliptin Metformin Tablets [1] - The drug is indicated for the treatment of type 2 diabetes patients who have inadequate blood sugar control with metformin monotherapy or are currently receiving a combination of both treatments [1] Industry Summary - The acceptance of the drug application highlights the ongoing demand and market potential for diabetes medications, particularly for combination therapies that enhance blood sugar control [1] - The drug contains 50mg of Sitagliptin and 850mg of Metformin per tablet, which aligns with current treatment protocols for managing type 2 diabetes [1]